MedDataX Logo

High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood

NCT ID: NCT00180791

Last Updated: 2007-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medulloblastoma Brain Tumors Neuroectodermal Tumors, Primitive

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Brain PNET

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etoposide, carboplatin, melphalan, cisplatin, thiotepa

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Medulloblastoma in patients less than 5 years of age
* Brain PNET in patients less than 10 years of age
* Histologically documented diagnosis
* Body weight of \> 8 kg

Exclusion Criteria

* Parents' refusal
Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chantal Kalifa, MD

Role: PRINCIPAL_INVESTIGATOR

Gustave Roussy, Cancer Campus, Grand Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Gustave Roussy

Villejuif, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chantal Kalifa, MD

Role: CONTACT

Phone: 33 1 42 11 4166

Email: [email protected]

Agnès Laplanche, MD

Role: CONTACT

Phone: 33 1 42 11 4127

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chantal Kalifa, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PNET HR

Identifier Type: -

Identifier Source: org_study_id